Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Chemie Grünenthal of Stolberg-am-Rhein Stories

2012-07-12 02:28:15

BEDMINSTER, N.J., July 12, 2012 /PRNewswire/ -- This year's 39th Annual Meeting and Exposition of the Controlled Release Society (CRS) will take place in Quebec City, Canada from July 15-18, 2012. Grunenthal's participation in the event will include a booth exhibition as well as hosting an interactive Releasing Technology Workshop. The annual CRS conference offers opportunities to learn about the most recent advancement in drug delivery science, one of which is Grunenthal's tamper resistant...

2012-04-23 02:27:39

AACHEN, Germany, April 23, 2012 /PRNewswire/ -- Apply for 2012 at http://www.e-g-g.info Young scientists from across Europe are invited to apply for the EFIC-Gruenenthal Grant (E-G-G) 2012, one of the most highly regarded pain research grants worldwide. Provided by the European Federation of IASP(R) Chapters (EFIC(R)) and the pharmaceutical company and pain expert Gruenenthal GmbH, this grant supports young scientists early in their career in conducting innovative and...

2011-11-17 12:42:00

SEATTLE, Nov. 17, 2011 /PRNewswire/ -- Attorneys representing a group of U.S. citizens suffering from severe birth defects they believe were caused by the drug thalidomide have filed a lawsuit in federal court to compel the FDA to release records they believe will show the drug was widely distributed in the United States. The suit seeks to compel the FDA to respond to a number of Freedom of Information Act (FOIA) requests by attorneys representing the patients, some filed more than a...

2010-09-22 07:59:00

MILAN, September 22, 2010 /PRNewswire/ -- After having handled the worldwide launch of tapentadol, the innovative drug for the severe acute pain, Alberto Grua has been appointed Grunenthal Europe and Australia Executive Vice President. Beyond the responsibility of the Grunenthal subsidiaries Grunin both continents, Grua will be also a member of the Group Operating Committee of Grunenthal Corporation. (Photo: http://www.newscom.com/cgi-bin/prnh/20100922/409552 ) Previously, Grua...

2010-08-30 14:37:00

RARITAN, N.J., Aug. 30 /PRNewswire/ -- Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation. In addition, this study compared oxycodone controlled release (CR) to placebo as an active control. Tapentadol ER vs. Placebo The study demonstrated that a significantly higher percentage of patients...

2010-05-03 07:00:00

RARITAN, N.J., May 3 /PRNewswire/ -- Data on tapentadol for the relief of acute and chronic pain, as well as patient and prescriber perceptions of oxycodone immediate-release treatments, will be presented at the 29th Annual Scientific Meeting of the American Pain Society (APS) May 6-8, 2010. Four of the 12 poster presentations will review analyses of tapentadol data, including a post-hoc analysis of a Phase 3 tolerability study on NUCYNTA® (tapentadol) tablets for acute...

2009-04-12 08:50:16

Thalidomide victims once snubbed by the German government are being offered compensation for birth defects caused by the drug, officials say. The German family ministry has announced it will temporarily waive a 26-year-old ban on considering thalidomide relief claims from foreign countries until the end of 2010, thus enabling victims from around the world to collect damages on the drug formerly made by the German company Grunenthal, The Sunday Times of London reported. Germany since 1983 has...